MiMedx Group (NASDAQ:MDXG) Reaches New 12-Month Low – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.13 and last traded at $5.2050, with a volume of 240768 shares traded. The stock had previously closed at $5.30.

Analysts Set New Price Targets

MDXG has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho decreased their price target on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Finally, Lake Street Capital decreased their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average target price of $10.67.

MiMedx Group Trading Down 0.6%

The firm has a market cap of $756.79 million, a price-to-earnings ratio of 18.93 and a beta of 1.57. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $6.46 and a 200-day moving average price of $6.83.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08. The firm had revenue of $113.73 million for the quarter, compared to the consensus estimate of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, research analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. This trade represents a 19.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the business. Trigran Investments Inc. grew its holdings in shares of MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after acquiring an additional 790,901 shares in the last quarter. Vanguard Group Inc. boosted its position in MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after purchasing an additional 382,623 shares during the last quarter. First Light Asset Management LLC grew its stake in MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after purchasing an additional 1,725,458 shares in the last quarter. Dimensional Fund Advisors LP increased its position in MiMedx Group by 4.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,382,333 shares of the company’s stock worth $16,628,000 after purchasing an additional 99,084 shares during the last quarter. Finally, Punch & Associates Investment Management Inc. raised its stake in shares of MiMedx Group by 1.6% during the 3rd quarter. Punch & Associates Investment Management Inc. now owns 2,005,014 shares of the company’s stock worth $13,995,000 after purchasing an additional 31,082 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.